Navigation Links
Newer Rheumatoid Arthritis Drugs Lower Production of B Cells
Date:1/25/2008

Though millions take Enbrel, Humira, Remicade, mechanism behind medications was unclear

FRIDAY, Jan. 25 (HealthDay News) -- Certain drugs used to treat rheumatoid arthritis (RA) provide a powerful, previously unknown, benefit for the immune system, say University of Rochester Medical Center researchers.

They found that drugs known as anti-TNF compounds -- including Enbrel, Humira and Remicade -- help reduce the activity of abnormal B cells that play a role in autoimmune diseases such as RA and lupus. TNF is a chemical messenger that fires up the immune system. Anti-TNF drugs inhibit TNF.

The findings, published in the Jan. 15 issue of The Journal of Immunology, suggest that these drugs improve the health of patients in a way that hadn't been recognized, the researchers said.

"The most important considerations for any drug are: Is it safe, and does it work? The answer is certainly 'yes' to both questions for these anti-TNF compounds. The drugs have revolutionized the treatment of patients with rheumatoid arthritis. But it also turns out that, even though millions of patients been treated with these medications, we really haven't understood to a significant degree how they actually work," research co-leader Dr. Ignacio Sanz, a professor of medicine, microbiology and immunology, said in a prepared statement.

Sanz and his colleagues studied 45 adults with RA and 22 healthy adults. Some of the RA patients received the anti-TNF medication etanercept (Enbrel), some received an older medication called methotrexate, and others received both drugs.

Among patients who took etanercept, there was a 40 percent drop in the percentage of B cells in lymph tissue. The RA patients who took etanercept also had about 75 percent fewer germinal centers, and the germinal centers that did exist in these patients were smaller and less organized than those in patients who didn't receive anti-TNF therapy.

Germinal centers are structures in the lymph system that appear when people have infections. These centers produce B cells, which the body uses to mark invaders for destruction. In healthy people, germinal centers fade away after recovery from an infection. But in people with RA and other chronic autoimmune diseases, germinal centers remain active.

"This is a critical piece of the immune system. Germinal centers are where crucial education of the B cell takes place -- where they learn which cells to attack and which ones not to. Dysregulation in germinal center reactions may play a role in many autoimmune diseases," study co-leader Dr. Jennifer Anolik, an assistant professor of medicine, said in a prepared statement.

Anti-TNF drugs appear to disrupt the formation of special cells (follicular dendritic cells) that link germinal centers, which decreases the number of abnormal B cells, Anolik said.

"There is a lot of excitement about the role of B cells in autoimmune disease. The connection between TNF-targeted therapy and B cells in rheumatoid arthritis really hasn't been appreciated," she said.

Anolik is about to launch a study to compare how two different anti-TNF drugs affect B cells in RA patients. The findings could help explain why some RA patients respond well to certain drugs but not others.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about autoimmune disorders.



-- Robert Preidt



SOURCE: University of Rochester Medical Center, news release, Jan. 21, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer antidepressants led to less, not more, teen suicides
2. Newer Antibiotic Speeds TB Healing
3. Newer radiation treatment easier for some throat cancer patients
4. Newer Anticlotting Drug Safe, Effective for Heart Surgeries
5. Newer Sedative Might Help Patients on Ventilators
6. Biologic treatment for rheumatoid arthritis and the risk of cancer
7. Genes Boost Risk for Rheumatoid Arthritis, Lupus
8. The genes involved in rheumatoid arthritis identified
9. Genome Area Linked to Rheumatoid Arthritis
10. Meditation therapy for rheumatoid arthritis patients
11. Meditation May Help Rheumatoid Arthritis Sufferers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Rheumatoid Arthritis Drugs Lower Production of B Cells
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
Breaking Medicine Technology: